{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:42:04Z","timestamp":1791499324702,"version":"4.3.4"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"\n BACKGROUND AND OBJECTIVES:<\/jats:title>\n There is no consensus on optimal treatment duration for propranolol in infantile hemangioma (IH). We evaluated the efficacy and safety of oral propranolol solution administered for a minimum of 6 months up to a maximum of 12 months of age in high-risk IH.<\/jats:p>\n <\/jats:sec>\n \n METHODS:<\/jats:title>\n This single-arm, open-label, phase 3 study was conducted in patients aged 35 to 150 days with high-risk IH in 10 hospitals between 2015 and 2017. The study comprised a 6-month initial treatment period (ITP) plus continuation up to 12 months of age if complete success was not achieved, a follow-up, and a retreatment period. Patients received oral propranolol twice daily (3 mg\/kg per day). The primary end point was the success rate at the end of the ITP. Furthermore, the persistence of IH response and efficacy of retreatment was evaluated.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n The success rate after 6 months of treatment was 47%, increasing to 76% at the end of the ITP. Of the patients who achieved success, 68% sustained success for 3 months without treatment, and 24% required retreatment. Of the 8 patients who were retreated, 7 achieved success. Adverse events, reported by 80% of patients, were mild, which were expected in this population or known propranolol side effects.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS:<\/jats:title>\n Oral propranolol administered beyond 6 months and up to 12 months of age meaningfully increases the success rate in high-risk IH. Success was sustained in most patients up to 3 months after stopping treatment. Retreatment was efficacious, and the safety profile satisfactory.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.2017-3866","type":"journal-article","created":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T07:25:45Z","timestamp":1533540345000},"source":"Crossref","is-referenced-by-count":39,"title":["Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma"],"prefix":"10.1542","volume":"142","author":[{"given":"Eulalia","family":"Baselga","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozenna","family":"Dembowska-Baginska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Instytut Pomnik\u2013Centrum Zdrowia Dziecka, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Przewratil","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Surgery, Samodzielny Publiczny Zaklad Opieki Zdrowotnej Uniwersytecki Szpital Kliniczny, Uniwersytetu Medycznego w \u0141odzi, \u0141\u00f3d\u017a, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Antonia","family":"Gonz\u00e1lez-Ense\u00f1at","sequence":"additional","affiliation":[{"name":"Dermatology Service, Hospital Sant Joan de Deu, Esplugues de Llobregat, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Wyrzykowski","sequence":"additional","affiliation":[{"name":"Department of Surgery and Urology for Children and Adolescents, Copernicus Podmiot Leczniczy Sp. z o.o, Gda\u0144sk, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Torrelo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Carlos","family":"L\u00f3pez Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Departments of Pediatric Surgery and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Rych\u0142owska-Pruszy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology for Children and Youth, Instytut Matki i Dziecka, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"de Lucas-Laguna","sequence":"additional","affiliation":[{"name":"Dermatology, Hospital Infantil La Paz, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altea","family":"Esteve-Martinez","sequence":"additional","affiliation":[{"name":"Polyclinic Dermatology, Hospital General Universitario de Valencia, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Ro\u00e9","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Zaim","sequence":"additional","affiliation":[{"name":"Institut de Recherche Pierre Fabre, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Menon","sequence":"additional","affiliation":[{"name":"Institut de Recherche Pierre Fabre, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Gautier","sequence":"additional","affiliation":[{"name":"Institut de Recherche Pierre Fabre, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Lebb\u00e9","sequence":"additional","affiliation":[{"name":"Pierre Fabre M\u00e9dicament, Boulogne-Billancourt, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athmane","family":"Bouroubi","sequence":"additional","affiliation":[{"name":"Institut de Recherche Pierre Fabre, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Delarue","sequence":"additional","affiliation":[{"name":"Pierre Fabre Dermatologie, Lavaur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Voisard","sequence":"additional","affiliation":[{"name":"Pierre Fabre Dermatologie, Lavaur, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2018,9,1]]},"reference":[{"issue":"4","key":"2021120916241096100_B1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0190-9622(97)70183-X","article-title":"Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines\/Outcomes Committee.","volume":"37","author":"Frieden","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2021120916241096100_B2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1525-1470.2008.00626.x","article-title":"Infantile hemangiomas: how common are they? A systematic review of the medical literature.","volume":"25","author":"Kilcline","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"2021120916241096100_B3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1525-1470.2005.00102.x","article-title":"Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA.","volume":"22","author":"Frieden","year":"2005","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"2021120916241096100_B4","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1542\/peds.2006-0413","article-title":"Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment.","volume":"118","author":"Haggstrom","year":"2006","journal-title":"Pediatrics"},{"issue":"11","key":"2021120916241096100_B5","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jamadermatol.2016.2905","article-title":"Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy.","volume":"152","author":"Baselga","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"3, pt 1","key":"2021120916241096100_B6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1542\/peds.101.3.446","article-title":"Growing up with a facial hemangioma: parent and child coping and adaptation.","volume":"101","author":"Tanner","year":"1998","journal-title":"Pediatrics"},{"issue":"24","key":"2021120916241096100_B7","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy.","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"2021120916241096100_B8","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-3458","article-title":"Propranolol for severe infantile hemangiomas: follow-up report.","volume":"124","author":"Sans","year":"2009","journal-title":"Pediatrics"},{"issue":"6","key":"2021120916241096100_B9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1525-1470.2011.01551.x","article-title":"Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study.","volume":"28","author":"Bertrand","year":"2011","journal-title":"Pediatr Dermatol"},{"issue":"12","key":"2021120916241096100_B10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/archdermatol.2011.203","article-title":"Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis.","volume":"147","author":"Price","year":"2011","journal-title":"Arch Dermatol"},{"issue":"2","key":"2021120916241096100_B11","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-0029","article-title":"A randomized controlled trial of propranolol for infantile hemangiomas.","volume":"128","author":"Hogeling","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"2021120916241096100_B12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bjd.12217","article-title":"Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age.","volume":"169","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2013","journal-title":"Br J Dermatol"},{"issue":"8","key":"2021120916241096100_B13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma.","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","journal-title":"N Engl J Med"},{"key":"2021120916241096100_B14","doi-asserted-by":"crossref","first-page":"43292","DOI":"10.1038\/srep43292","article-title":"When to stop propranolol for infantile hemangioma.","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"2021120916241096100_B15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bjps.2010.06.010","article-title":"Low-dose propranolol for infantile haemangioma.","volume":"64","author":"Tan","year":"2011","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"6","key":"2021120916241096100_B16","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ophtha.2010.10.031","article-title":"Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children.","volume":"118","author":"Al Dhaybi","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"2021120916241096100_B17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jpedsurg.2011.10.058","article-title":"Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations.","volume":"47","author":"Talaat","year":"2012","journal-title":"J Pediatr Surg"},{"issue":"6","key":"2021120916241096100_B18","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/bjd.12432","article-title":"Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.","volume":"169","author":"Ahogo","year":"2013","journal-title":"Br J Dermatol"},{"issue":"4","key":"2021120916241096100_B19","doi-asserted-by":"crossref","first-page":"e20151754","DOI":"10.1542\/peds.2015-1754","article-title":"Rebound growth of infantile hemangiomas after propranolol therapy.","volume":"137","author":"Shah","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"2021120916241096100_B20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archdermatol.2011.926","article-title":"Measuring the severity of infantile hemangiomas: instrument development and reliability.","volume":"148","author":"Haggstrom","year":"2012","journal-title":"Arch Dermatol"},{"issue":"6","key":"2021120916241096100_B21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"1","key":"2021120916241096100_B22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2340\/00015555-1847","article-title":"Haemangioma Family Burden: creation of a specific questionnaire.","volume":"95","author":"Boccara","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"2021120916241096100_B23","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/PRS.0b013e318208d2ac","article-title":"Untreated hemangiomas: growth pattern and residual lesions.","volume":"127","author":"Bauland","year":"2011","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"2021120916241096100_B24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jpeds.2006.12.003","article-title":"Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics.","volume":"150","author":"Haggstrom","year":"2007","journal-title":"J Pediatr"},{"issue":"1","key":"2021120916241096100_B25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1542\/peds.2012-1691","article-title":"Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.","volume":"131","author":"Drolet","year":"2013","journal-title":"Pediatrics"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2017-3866\/1064347\/peds_20173866.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2017-3866\/1064347\/peds_20173866.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T04:36:58Z","timestamp":1639111018000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/142\/3\/e20173866\/38572\/Efficacy-of-Propranolol-Between-6-and-12-Months-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9,1]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2017-3866","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]},"article-number":"e20173866"}}